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Abstract
The number of reports of clinical trials grows by hundreds every week. However, this does not
mean that people making decisions about healthcare are finding it easier to obtain reliable
knowledge for these decisions. Some of the information is unreliable. Systematic reviews are
helping to resolve this by bringing together the research on a topic, appraising and summarising it.
But the quality of these reviews depends greatly on the quality of the studies, and this usually means
the quality of their reports. If there are fundamental flaws within a study, such as the use of
inappropriate 'randomisation' techniques in the context of reviews of the effects of interventions,
the reviewers will not be able to fix these. Worse still, if they are not aware of underlying flaws,
they might make incorrect judgements about the quality of the research in their review. A study by
Wu and colleagues of 'randomised trials' from China provides a reminder of the cautious approach
needed by users of scientific articles. They contacted the authors of more than 2000 research
articles, which purported to be reports of randomised trials; and concluded that ten of every 11
studies claiming to be a randomised trial probably did not use random allocation. Better education
of researchers, peer reviewers and editors about what is, and is not, a properly randomised trial is
needed; along with better reporting of the details for how participants were allocated to the
different interventions. Systematic reviewers must be cautious in making assumptions about the
conduct of trials based on simple phrases about the trial methodology, rather than a full description
of the methods actually used. It's not that you can't believe anything that you read in the papers,
just that you cannot believe everything.
Introduction
There are ever increasing numbers of papers available in
healthcare journals, and even more articles appearing in
newer media such as the Internet. At first sight, the depth
and breadth of this material might mean that people mak-
ing decisions about their own care or that of others have
never had it so good. Surely, they will be able to find
research in the relevant topic area. They will. But the prob-
lem is: some of this research might not be reliable and the
decision maker might not be able to find a sufficiently
unbiased collection of the research to help her to make
the right decision.
Discussion
For decisions about the effects of health care, randomised
trials should boost the chances that comparisons are not
confounded by factors other than the interventions being
compared. They are, therefore, a more reliable guide for
estimates of the differences between the actual interven-
tions [1]. However, the problem of publication bias
means that trials which have findings that do not favour
the experimental intervention are less likely to be pub-
lished quickly or at all [2,3], making the available litera-
ture a potentially biased and unreliable source of
knowledge.
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Trials 2009, 10:55 http://www.trialsjournal.com/content/10/1/55It is possible that the recent growth in the number of trial
reports being published is a sign that publication bias is
being overcome. During this first decade of the twenty-
first century, at least 25,000 reports of randomised or con-
trolled trials have been published each year [4]. However,
we will not know if this is a fair reflection of the volume
of research being done until recent initiatives on wide-
spread trial registration provide a means of tracking large
cohorts of trials over time, and there may still be some
way to go before all trials are registered prospectively. For
example, the World Health Organisation's International
Clinical Trials Registry Platform shows that nearly 20,000
trials were registered in the constituent registers in 2008,
an increase of more than 4000 compared to 2007 [4].
However, it will only be through the routine reporting of
the findings of all trials that publication bias will be elim-
inated [5].
In the last two decades, the growth in another type of
research article might also hold out some hope for deci-
sions makers. Systematic reviews bring together the find-
ings of the individual studies relevant to a specific
question, and thousands are published each year [6]. But,
the authors of these reviews face the challenge that the
quality of their work depends greatly on the quality of the
studies they review, which usually means the quality of
the reports of these studies. If there are fundamental flaws
in the underlying study design, such as the use of inappro-
priate 'randomisation' techniques, the researchers work-
ing on the systematic review will not be able to fix these.
Worse still, if they are not aware of the underlying flaws,
they might make incorrect judgements about the quality
of the research they are reviewing.
This brings us to the study by Wu and colleagues of 'ran-
domised trials' in what may become one of the largest
sources of healthcare research evidence, China [7], and its
reminder that readers of scientific articles need to be cau-
tious in their interpretation. Wu et al. gathered together
more than 3000 research articles that had been published
in Chinese journals in just over 10 years from 1994, which
purported to be reports of randomised trials. They con-
ducted telephone interviews with the authors of 2235 of
these reports and found that their answers were indicative
of the conduct of a properly randomised trial for just 207
of these reports. Ten of every 11 reports claiming to be a
randomised trial probably were not.
This work confirmed what had been found by some of the
authors on a smaller scale within the context of systematic
review of Chinese medicinal herbs for treating measles. Of
the 28 reports of randomised trials they found, Gu et al.
were able to contact the authors of 19. Their discussions
led them to conclude that none of these were properly
randomised trials, casting sufficient doubt on the other
nine studies for the authors to decide that none of the
studies should be included in their review [8].
Wu et al. suggest a few reasons for the poor quality of the
information reported for this large amount of Chinese
research, and point to some solutions. These will need to
include better education of researchers, peer reviewers and
editors about what is, and is not, a properly randomised
trial. Better reporting of how the participants in a trial
were allocated to the different interventions will also be
needed to help the reader to decide for herself whether or
not a trial being described as 'randomised', really was; as
proposed in the CONSORT statement [9].
Conclusion
The message for systematic reviewers is to continue to be
cautious in making assumptions about the conduct of tri-
als based on simple phrases about the methodology of the
research, rather than a full description of the methods
actually used. Decision makers in health care need to be
presented with reliable evidence in order to make their
decisions as reliable as possible. People conducting pro-
spective studies need, therefore, to ensure that the infor-
mation they present is reliable and systematic reviews
need to appraise this information carefully and to distin-
guish between the label on a study and what really went
on "inside the tin".
It's not that you can't believe anything that you read in the
papers, just that you cannot believe everything.
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